These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 28099741)

  • 61. [Medical abortion provided by telemedicine to women in Latin America: complications and their treatment].
    Larrea S; Palència L; Perez G
    Gac Sanit; 2015; 29(3):198-204. PubMed ID: 25770915
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Medical abortion alternatives to mifepristone.
    Creinin MD; Pymar HC
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):127-32, 150. PubMed ID: 10846321
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Women's opinions on the home management of early medical abortion in the UK.
    Lohr PA; Wade J; Riley L; Fitzgibbon A; Furedi A
    J Fam Plann Reprod Health Care; 2010 Jan; 36(1):21-5. PubMed ID: 20067668
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol.
    Ashok PW; Flett GM; Templeton A
    Lancet; 1998 Aug; 352(9127):542-3. PubMed ID: 9716062
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Study supports the introduction of early medical abortion in Turkey.
    Akin A; Kocoglu GO; Akin L
    Reprod Health Matters; 2005 Nov; 13(26):101-9. PubMed ID: 16291491
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion.
    Dahiya K; Mann S; Nanda S
    Arch Gynecol Obstet; 2011 Jul; 284(1):59-63. PubMed ID: 20652288
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
    Tsereteli T; Chong E; Louie K; Bokhua Z; Winikoff B
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):367-71. PubMed ID: 27449873
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Stocking and over-the-counter sale of misoprostol for medical abortion in Ghana's community pharmacies: comparison of questionnaire and mystery client survey.
    Ganle JK; Busia NT; Baatiema L
    Int J Pharm Pract; 2020 Jun; 28(3):267-274. PubMed ID: 31746501
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The illegal market for gender-related drugs as portrayed in the Brazilian news media: the case of misoprostol and women].
    Diniz D; Castro R
    Cad Saude Publica; 2011 Jan; 27(1):94-102. PubMed ID: 21340108
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Abortion politics in Cambodia social history, local forms and transnational issues.
    Hancart Petitet P
    Glob Public Health; 2018 Jun; 13(6):692-701. PubMed ID: 28730874
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anxieties and attitudes towards abortion in women presenting for medical and surgical abortions.
    Wiebe ER; Trouton KJ; Fielding SL; Grant H; Henderson A
    J Obstet Gynaecol Can; 2004 Oct; 26(10):881-5. PubMed ID: 15507198
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Estimating the frequency of induced abortion: a comparison of two methods].
    Olinto MT; Moreira Filho Dde C
    Rev Panam Salud Publica; 2004 May; 15(5):331-6. PubMed ID: 15231081
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development and evaluation of the abortion attributes questionnaire.
    Harvey SM; Nichols MD
    J Soc Issues; 2005 Mar; 61(1):95-107. PubMed ID: 17073025
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Stakeholder perceptions of misoprostol: a qualitative investigation.
    Bazzano AN; Jones L; Ngo TD
    Int J Womens Health; 2014; 6():389-93. PubMed ID: 24748820
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gender diversity among aspiration-abortion patients.
    Janiak E; Braaten KP; Cottrill AA; Fulcher IR; Goldberg AB; Agénor M
    Contraception; 2021 Jun; 103(6):426-427. PubMed ID: 33545129
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Moving from legality to reality: how medical abortion methods were introduced with implementation science in Zambia.
    Fetters T; Samandari G; Djemo P; Vwallika B; Mupeta S
    Reprod Health; 2017 Feb; 14(1):26. PubMed ID: 28209173
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Abortion choices among women in Cambodia after introduction of a socially marketed medicated abortion product.
    Sotheary K; Long D; Mundy G; Madan Y; Blumenthal PD
    Int J Gynaecol Obstet; 2017 Feb; 136(2):205-209. PubMed ID: 28099741
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Towards safe abortion access: an exploratory study of medical abortion in Cambodia.
    Petitet PH; Ith L; Cockroft M; Delvaux T
    Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):47-55. PubMed ID: 25702068
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Provision of harm-reduction services to limit unsafe abortion in Tanzania.
    Kahabuka C; Pembe A; Meglioli A
    Int J Gynaecol Obstet; 2017 Feb; 136(2):210-214. PubMed ID: 28099731
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of early induced medical abortion with mifepristone when beginning progestin-only contraception on the same day.
    Douthwaite M; Candelas JA; Reichwein B; Eckhardt C; Ngo TD; Domínguez A
    Int J Gynaecol Obstet; 2016 Jun; 133(3):329-33. PubMed ID: 26969144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.